Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists by Jäger, M & Rössler, W
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Attitudes towards long-acting depot antipsychotics: A survey of
patients, relatives and psychiatrists
Jäger, M; Rössler, W
Jäger, M; Rössler, W (2010). Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and
psychiatrists. Psychiatry Research, 175(1-2):58-62.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Psychiatry Research 2010, 175(1-2):58-62.
Jäger, M; Rössler, W (2010). Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and
psychiatrists. Psychiatry Research, 175(1-2):58-62.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Psychiatry Research 2010, 175(1-2):58-62.
Attitudes to long-acting depot antipsychotics: A survey of patients, 
relatives and psychiatrists 
 
Matthias Jäger *, Wulf Rössler 
Department of General and Social Psychiatry, Psychiatric University Hospital Zurich, Lenggstrasse 31, 8032 
Zurich, Switzerland 
  
 
Abstract 
 
In many countries fewer than 20% of individuals with schizophrenia receive depot 
antipsychotic medication. Frequently stated reasons are psychiatrist’s, patient’s and relative’s 
objections to depot treatment. This is the first study that directly compares the attitudes to 
depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire 
about their attitudes to depot antipsychotics was completed by 255 participants (83 patients 
diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, 
not directly related to the patients). Patients were more negative towards depot injections than 
psychiatrists and relatives. They particularly fear to be constricted in their autonomy when 
treated with depot antipsychotics and that injections might be painful. About 67% of all 
patients in our sample did not receive information about depot antipsychotics by their 
psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic 
episode. Psychiatrists use depot antipsychotics in a conservative way although they attribute 
positive traits to the method. Patients’ negative attitudes might relate to the low level of 
information. To enhance the use of depot antipsychotics, information practices of 
psychiatrists should be improved. Patients should be informed about different applications 
forms already during early stages of the illness. 
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1. Introduction 
 
Schizophrenia and related disorders affect 1 to 1.5% of the general population. It is a 
costly disease due to its early onset and chronicity, the high utilization of mental health care 
resources, the lost productivity and the enormous burden imposed on patients and relatives 
(Nordt et al., 2006). The prevention of relapses remain a major public health challenge and 
improvements in this area can have tremendous impact on morbidity, mortality and quality of 
life, as well as on direct and indirect health care costs. There is strong evidence that frequent 
relapses can increase the likelihood of poorer long-term outcome (Wiersma et al., 1998; 
Harrison et al., 2001; Hill et al., 2004). Recently volumetric magnetic resonance imaging 
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studies confirmed that grey matter density loss occurs across the course of the illness in 
schizophrenia. This density loss appeared to be related to an increased number of psychotic 
episodes, with atypical antipsychotic medication attenuating these changes (Cahn et al., 2006; 
van Haren et al., 2008). Non-adherence is one of the main factors undermining successful 
pharmacological relapse prevention. The costs of non-adherence are significant, with an 
estimated 40% of the total costs of the illness being attributed to rehospitalisations (Weiden 
and Olfson, 1995). There are several reasons for non-adherence in patients suffering from 
schizophrenia as side effects, limited insight to the disease and a negative attitude to 
medication (Buckley et al., 2007). Moreover the relationship between the professional and the 
patient plays a crucial role with regard to the patient’s acceptance of medication (Naber and 
Karow, 2001). Additionally in many cases the attitudes and insight of the family and other 
relatives of the patient in the treatment of the mental disorder have great influence to patient’s 
adherence. There is still inadequate attention being paid to strategies which can enhance 
medication acceptance and adherence, including the more extensive use of depot 
antipsychotic administration (Kane et al., 1998). 
Research suggested that patients receiving conventional depot medication were significantly 
less likely to require hospital treatment than those who received conventional oral 
antipsychotics (Babiker, 1987; Davis et al., 1994). With the introduction of oral atypical 
antipsychotics, there has been initially a shift away from depot typicals to oral administration 
(Patel and David, 2005). Since the start of the 21st century a long-acting injectable 
formulation of an atypical antipsychotic is available as a new additional treatment option 
(Taylor et al., 2004). Several advantages of long-acting injections compared with oral forms 
of medication were found in many studies for instance the transparency of non-adherence and 
the higher stability of the blood concentration that seems to be beneficial for the effect and 
side-effect profiles (Gerlach, 1994). Disadvantages of depot antipsychotics include delayed 
disappearance of side effects after discontinuation, patient reluctance to accept injections and 
the feeling of being controlled. However, in many countries throughout the world fewer than 
20% of individuals with schizophrenia receive depot antipsychotic drugs. In Switzerland, the 
depot treatment rate of 5% was the lowest compared with other West-European countries 
(Kane et al., 1998).  
Research shows that psychiatrists often have a negative attitude towards conventional depot 
medication. These are often regarded as old fashioned and stigmatising and are considered to 
cause more side effects and thus also cause more legal problems than when oral medication is 
prescribed (Patel et al., 2003; Patel and David, 2005). Furthermore, second-generation long-
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acting injectable drugs are considered to be associated with high treatment costs (Heres et al., 
2006). Studies in which the patient’s satisfaction with a method of administering drugs is 
taken into account show that patients have a positive attitude towards depot medication 
(Pereira and Pinto, 1997; Walburn et al., 2001; Svedberg et al., 2003).  However, most 
findings included a selection bias because they focused on patients who were compliant with 
medication or received injections regularly. A recent survey confirms that preference of 
depots depends on the patient’s experience with the formulation (Heres et al., 2007). A 
negative attitude towards pharmacological treatment of mental diseases is sometimes found 
among patients’ families and friends. In society at large, both public opinion and the media 
often support the view that depot medication involves an element of coercion and causes more 
adverse effects. Much more information is needed for patients, relatives and the public to 
engender more balanced attitudes (Gerlach, 1995).  
This study aimed at investigating the current attitudes, beliefs and knowledge held by 
psychiatrists, patients and relatives concerning depot antipsychotics. We hypothesized that the 
low depot treatment rate in Switzerland could be attributed to the negative attitude of the 
psychiatrists towards this method of administering rather than to patient’s denial. 
Additionally, we assumed that patients were underinformed about different methods of 
administering antipsychotic drugs.  
 
2. Methods 
 
2.1. Subjects and procedure 
 
 We conducted a cross-sectional survey using 3 not directly related samples of patients, 
psychiatrists and relatives. The study was carried out in 2006 and typical as well as atypical 
depot formulations were available at the study site. Patients included had to comply with the 
following criteria: age between 18 and 65 years, diagnosis of a schizophrenic disorder (ICD-
10: F2), current inpatient or outpatient psychiatric treatment and an antipsychotic medication 
for at least 6 months, sufficient knowledge of the German language, currently no acute 
psychotic episode. Participants were recruited in inpatient and outpatient institutions of the 
Department of General and Social Psychiatry, University of Zurich. During six months all 
patients complying with the inclusion criteria were asked if they would participate. If so, 
written informed consent was obtained and the patient completed the questionnaire. 83 
patients (34%) of the potential participants were willing to participate. 
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All 451 registered psychiatrists in the canton of Zurich received an information sheet, the 
questionnaire and a stamped reply envelope. 81 (18%) returned a fully completed 
questionnaire after 6 weeks. Two additional psychiatrists responded that they had no 
experience with depot antipsychotics and therefore were not able to complete the 
questionnaire. 
The 9 regional Associations of Relatives of schizophrenic and psychiatric patients in the 
German speaking part of Switzerland were asked to participate. All associations distributed 
the questionnaires among their members and returned 91 completed questionnaires in total. 
The regional Associations received a lump sum for their participation. No response rate 
calculation was possible for the relatives because we could not reconstruct the number of 
relatives that were asked to complete the questionnaire by the regional relatives’ associations. 
The local ethics committee has confirmed the study in accordance with the Declaration of 
Helsinki. 
 
2.2. Instrument 
 
 The questionnaire was designed especially for the study based on questions used in 
former investigations with comparable objectives. Some of the questions concerning attitudes 
towards medication were taken from the DAI-10 Drug Attitude Inventory (Hogan et al., 
1983). The questionnaire included both open and multiple choice questions concerning: 
Demographic data, general information about antipsychotics, knowledge about and 
experience with depot antipsychotic medication, statements to possible advantages and 
disadvantages. Medication history of depot antipsychotics was confirmed by checking 
patients’ records. 
 
2.3. Statistical analyses 
 
 Anonymised data was entered into a database and analysed with SPSS 15.0 for 
Windows (Statistical Package for the Social Sciences, Lead Technologies, Inc., Chicago, 
2006). To test for any group differences in attitudes towards medication in general (patients, 
psychiatrists and relatives) and in being informed about application formulations of 
antipsychotics (patients with and without experience in depot treatment), we used two-tailed 
χ2  tests and Fisher’s exact test, respectively. 
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Statements concerning putative advantages and disadvantages of depot formulations were to 
be rated on a 5 point scale ranging from 1 = fully agree to 5 = fully disagree. With respect to 
attitudes towards depot formulations the three samples were compared by means of analysis 
of variance (ANOVA). Post hoc tests were calculated with the Tukey-HSD test. Due to the 
high number of comparisons (16) level of significance was adjusted to P < 0.003 to avoid 
alpha-error accumulation. Differences between the patients’ subgroups with and without 
depot experience were analysed prior to the ANOVA using t-tests. The significance level was 
set at P <0.05 (two-tailed) except for those analyses where the use of Bonferroni correction 
raised the significance level to 0.003. 
 
3. Results 
 
3.1. Description of the samples 
 
Among the participating psychiatrists 40% were female. The mean age was 54 years 
(S.D. 8.3). 87% worked in their own office practice. The mean number of years of psychiatric 
experience was 20 years (S.D. 8.7). All psychiatrists had experience in treating patients with 
schizophrenic disorder. The mean number of treated patients per year (caseload) was 80 (S.D. 
57). The mean rate of patients with schizophrenic diagnosis was 15%. All of the psychiatrists 
had experience in treatment with depot formulations. 42% of them had the possibility to apply 
the injections in their own office practice.  
Among the participating patients 37% were female. The mean age was 40 years (S.D. 11.7). 
At the time of investigation 29% of the patients were treated in an outpatient setting, 71% 
were inpatients. 32% of the inpatients were involuntarily admitted. The mean age at onset of 
the disorder was 27 years (S.D. 9), the mean number of hospitalisations was 6 (S.D. 7). 65% 
of the patients were diagnosed as schizophrenic, 18% as schizoaffective and 17% had another 
diagnose of the schizophrenic spectrum. 26% of the patients had experience with depot 
formulations either at the time of investigation or earlier.  
Among the relatives 40% were female. 86% were relatives of a patient with schizophrenia, 
14% were relatives of patients with another diagnosis of the schizophrenic spectrum. 28% 
were relatives of patients with experience with depot antipsychotic treatment. 
 
3.2. Attitudes towards medication in general 
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All groups concordantly agreed with the statement that medication was important in 
the treatment of psychiatric disorders. Table 1 shows the percentage of participants by sample 
that agreed with the respective statements concerning attitudes towards medication partially 
taken from the DAI-10 Drug Attitude Inventory (Hogan et al., 1983). 
 
Insert table 1 about here 
 
3.3. Information about formulations of antipsychotics 
 
Among the psychiatrists 75% quoted that they informed their patients generally about 
different formulations including the option of depot treatment and 59% also refer to 
supplemental sources of information (web, brochures etc.). Nevertheless, 68% of the 
psychiatrists believe that patients are not sufficiently informed about different methods of 
administering antipsychotic drugs, while 65% of the patients stated that they were well 
informed about this issue. 67% of all patients did not receive information about depot 
antipsychotics by their psychiatrist. Table 2 shows the level of information of the patient 
subgroups with and without experience in depot antipsychotic treatment respectively. 
 
Insert table 2 about here 
 
3.4. Attitudes towards depot application 
 
Table 3 displays the mean values of the 5 point scales to rate the respective statements 
concerning advantages and disadvantages of depot formulations and statements requiring 
pharmacological knowledge about antipsychotics. Thereby, higher values indicate 
disagreement with the respective statement. In order to account for differences between 
patients with and without depot experience we first conducted t-test analyses to compare the 
mean ratings of the subgroups. We could not find differences on any of the items so we did 
not control for the influence of experience with depot antipsychotic drugs in the ANOVA 
analysis. Patients consistently rather disagree with almost all statements that indicate possible 
advantages of depot formulations; at least they have a more negative attitude than relatives. 
Psychiatrists only consent with patients with respect to the statement that depot formulations 
do not have more advantages than oral formulations. Almost all the statements referring to 
potential disadvantages of depot antipsychotics were supported by patients rather than by 
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psychiatrists and relatives. Psychiatrists rather rejected these statements, while relatives were 
more neutral. As one might expect the four statements requiring knowledge about 
antipsychotics were appropriately evaluated by psychiatrists rather than by patients and 
relatives that mostly rated them neutrally. They only seemed to know that there were more 
antipsychotics available in oral as in depot formulation.  
 
Insert table 3 about here 
 
3.5. Reasons for changing the formulation 
 
Among the psychiatrists 88% prefer tablets and 12% depot injections as their preferred 
method of administering antipsychotic drugs. The following reasons were named for the 
preference of depots: patients are more compliant and thus more stable in psychopathological 
improvement, depots give the patient more safeness, the blood concentration of the active 
agent is more stable and a lower dose of is sufficient. The most frequently named reasons for 
changing the method of administering to depot injection were request of the patient (64%) and 
non-adherence (43%) followed by adverse reactions (33%) and insufficient antipsychotic 
effect (22%).  
More than 90% of the psychiatrists never or rarely recommend changing to depot after a first 
psychotic episode while 50% advise patients after several relapses to switch to depot 
injection. Psychiatrists stated that they would prescribe depot antipsychotics more frequently 
if patients would agree on changing the formulation and if there were more preparations 
available as depot injections.  
 
4. Discussion 
 
This is the first study that compares directly in one survey the attitudes to depot 
antipsychotics of psychiatrists, patients and relatives and one of the first on this issue since the 
introduction of an atypical depot formulation. One of the main findings is that patients in 
general are more negative towards depot injections than psychiatrists and relatives. Patients 
particularly fear to be constricted in their autonomy and that injections might be painful. This 
confirms the finding of Glazer and Kane (1992) that patients mostly reject depot medication 
due to fear of needles. In this respect, we can not confirm our hypothesis based on previous 
findings that patients generally have a positive attitude towards depot antipsychotics (Pereira 
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and Pinto, 1997; Walburn et al., 2001). An explanation for this could be that most of these 
studies assessed the attitudes of patients towards depot antipsychotic treatment in samples that 
currently received depot medication. In such samples a higher satisfaction with the current 
treatment can be expected. We could not find differentiated results concerning attitudes to 
depot formulation that depend on former or present experience of patients with depot 
medication (Heres et al., 2007). A reason for this might rely on the small sample size.  
Additionally, we investigated if patients were informed about different treatment options prior 
to antipsychotic treatment. One third of the patients declared to be insufficiently informed 
about different formulations. Among patients without experience in depot antipsychotic 
treatment almost 80% indicated that they were not informed by their psychiatrist about this 
method of administering antipsychotics. 90% of this subgroup stated that their psychiatrist 
never recommended changing the formulation to depot. Altogether, 67% of all patients in our 
sample did not receive information about depot antipsychotics by their psychiatrist. This 
result is consistent with previous findings (Heres et al., 2006) and might indicate a major 
shortcoming in information practices of psychiatrists. It could also reflect that these patients 
were informed but did not conceive the information or the psychiatrist thought that he 
provided the information but did not. It is known that patient and professional accuracy of 
recalled treatment decision in medical consultations is poor (Skinner et al., 2007).  
Psychiatrists support the advantages of depot antipsychotics but do not consider them to have 
more advantages than oral formulations. Three out of four psychiatrists declared to inform 
their patients about different formulations of antipsychotics in general though two thirds do 
not believe that patients are sufficiently informed. It is not possible to explain this discrepancy 
from the present study. Possibly psychiatrists consider their own patients to be well-informed 
but not the patients of their colleagues. Psychiatrists mostly recommend changing to depot 
application when patients are non-compliant or request depot medication. This is in line with 
a previous finding that mental health professionals perceive depot antipsychotics as a 
requirement for the treatment of those who were poorly adherent (Lambert et al., 2003). 
Changing to depot injections is almost never recommended after a first psychotic episode. 
This indicates that psychiatrists use depot antipsychotics in a conservative way although they 
attribute positive traits to the method that exist independently of the phase of the disorder. We 
could confirm a previous finding by Heres et al. (2006) that psychiatrists would use depot 
antipsychotics more often if there were more preparations available in depot form and if the 
patients would agree on changing the method of application. The latter might indicate that we 
face a vicious circle in the sense that psychiatrists anticipate a negative attitude of patients 
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towards depot injections that deters them from providing comprehensive information about 
this formulation that facilitates or maintains patient’s negative attitudes towards depot 
antipsychotics. 
More than 50% of the relatives had the opinion that patients were not taking their medication 
voluntarily. Moreover, relatives supported potential advantages of depot formulations 
stronger than patients. These findings are in concordance with the consideration that relatives 
do not trust patients’ medication adherence and thus might appreciate the advantage of depots 
that the patient securely receives the acting agent. The findings of Gerlach (1995) that 
relatives have a rather negative attitude towards pharmacological treatment of mental diseases 
can hence not be confirmed.  
 
4.1. Limitations 
 
Several limitations of our approach should be considered. The patients’ group includes 
individuals with schizophrenic disorder treated in outpatient, inpatient and involuntary 
settings. It is not a representative sample of patients with schizophrenia as patients having 
experience with depot formulations are overrepresented and more than 60% were male. 
Another possible bias is the high percentage of hospitalised patients who were involuntarily 
admitted and thus more negative about psychopharmacological treatment. Nevertheless, only 
patients in a stable psychopathological state with antipsychotic therapy were included. In 
addition, patients who agreed to participate were possibly more satisfied with their treatment 
and as such they were more compliant with medication. 
With regard to the psychiatrists’ sample a possible bias could be that almost all subjects were 
working in their own office practice while a change in the pharmacological regime including 
changing the formulation oftentimes takes place during hospitalisation. A second factor 
contributing to the selection bias could be that participating psychiatrists were interested in 
research and thus better informed about different formulations. In addition, only psychiatrists 
in the canton of Zurich were recruited which limits the possibility to generalize to all Swiss 
psychiatrists.  
The relatives’ group represents the attitudes of relatives of patients with a schizophrenic 
disorder in almost all German-speaking parts of Switzerland. All relatives were members of a 
Relatives’ Association that might indicate a higher involvement in the treatment of the often 
difficult patients. Thus, the relatives’ group might not represent the attitudes of all relatives of 
patients with a schizophrenic disorder. 
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Although the three samples were comparable in size and demographic structure they were not 
directly related to one another and the response rates for the psychiatrists and patients were 
low (18% and 34% respectively). No response rate calculation was possible for the relatives. 
These low response rates might introduce a strong risk of bias in the study samples as the 
results do not necessarily reflect the opinions of the stakeholders involved in the decision for 
an antipsychotic medication formulation. However, on the part of the psychiatrists, non-
response rather reflects indifference in relation to the issue of depot antipsychotic treatment 
than strong dedication to deliberate and improve treatment practices. If this was the case, the 
present results would not have changed in favour of more established information practices or 
more positive attitudes towards depot antipsychotics. Concerning non-responding patients we 
would assume that rather negative attitudes or unfavourable experience in conjunction with 
depot antipsychotics would deter them from participation in the study. Accordingly, it is less 
likely that our results would have been adjusted towards more favourable attitudes of patients. 
Future studies on the issue should consider comparing the attitudes of patients, psychiatrists 
and relatives that are directly related to each other in the treatment process. Such a design 
could reveal information about the factors influencing the choice of method of administration 
in the psychopharmacological treatment of a single patient, the interactions between the 
stakeholders, or the various stages in the process of making such a decision. In the present 
study, we cannot make conclusions with regard to the interactional factors on the part of 
psychiatrists and relatives that determine the negative attitudes of patients but only provide an 
insight into the attitudes of the three groups that might be either preconditions or 
consequences of the decision-making process. 
 
4.2. Clinical implications 
 
With respect to the results of the present study, we could not confirm our hypotheses 
that patients generally have a positive attitude to depot injections and that the low depot 
treatment rate in Switzerland could be attributed to the negative attitude of psychiatrists 
towards this method of administering rather than to patient’s reserves. Despite several 
limitations of the study we can conclude that patients rather hold a negative position toward 
depot treatment but especially depot-naïve patients are insufficiently informed about different 
treatment options. Psychiatrists seem to use depots in a conservative way and mostly 
introduce them after several episodes and for reasons of malcompliance. To enhance the use 
of depot antipsychotics in Switzerland more general information about antipsychotic 
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treatment options to patients, psychiatrists and relatives is needed to reduce prejudices. 
Patients should be informed about different applications forms already during early stages of 
the illness and they should be involved in the decision for a certain treatment form. A 
considerable part of patients treated with antipsychotic agents may prefer to get an injection 
every two to four weeks instead of remembering taking their pills every day. In the sense of a 
shared decision making process patients should know all treatment options and have the 
opportunity to introduce their preferences before decision making. A better information flow 
could be achieved by more extensive use of treatment information sheets or even the 
introduction of a written informed consent prior to antipsychotic treatment similar to informed 
consent prior to surgery or research participation. As long as depot injections are not provided 
to the patient in early phases of the illness as well as after multiple relapses depot 
antipsychotics will carry the image of coercion and thereby stigmatise the patient.  
The frequently mentioned fear of needles is a further problem that constricts the use of depots. 
In this context longer time intervals between two injections might be useful. Those patients 
otherwise might profit from an oral long acting form such as the first generation agent 
penfluridole. Another aspect is the fact that at the present time only one atypical agent is 
available as long acting injection form that deters psychiatrists to use depot antipsychotics. To 
improve the frequency of treatment with depot antipsychotics the development of more agents 
in this form is clearly indicated. This study indicates that the issue of depot antipsychotic 
treatment comprises precast opinions at the part of professionals as well as insufficient 
knowledge held by patients and relatives and hints at potential improvement of information 
practices in order to enhance a more balanced use of this method of administration.  
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Table 1: Attitudes towards medication in general: Proportion of respondents agreeing 
I agree with the following statement Psychiatrists 
(n=81) 
Patients 
(n =83) 
Relatives 
(n =91) 
χ2  
df=2 
P- value 
Medication is important in the treatment of 
psychiatric disorders 
99% 95% 100% 5.8 0.213 
Mostly, patients are taking their medication 
voluntarily 
95% 89% 46% 67.1 0.000 
The good things about medication outweigh the 
bad 
81% 68% 80% 12.8 0.012 
Oftentimes, patients are taking their medication 
only when they feel sick 
85% 43% 67% 44.5 0.000 
Oftentimes, patients find it unnatural for mind and 
body to be controlled by medication 
85% 41% 81% 47.4 0.000 
Only by staying on medication, patients can 
prevent getting sick 
90% 78% 96% 14.5 0.006 
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Table 2: Information about formulations of antipsychotics: Proportion of respondents 
agreeing 
I agree with the following statement Patients with depot 
experience 
(n =21) 
Patient without depot 
experience 
(n =61) 
P  
I knew about the possibility to receive 
antipsychotics as a depot injection 
90% 63% * 
My psychiatrists informed me about the 
option of depot antipsychotic treatment 
70% 21% *** 
My psychiatrist recommended me to change 
to depot antipsychotics  
60% 9% *** 
I obtained information about depot 
antipsychotics from other sources 
40% 22% ns 
I feel sufficiently informed about different 
formulations of antipsychotics 
76% 61% ns 
Significance (Fisher’s exact test): ns= not significant; *=P<0.05; **=P<0.01; ***=P<0.001; df=1 
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Table 3: Putative advantages and disadvantages of depot injections and statements acquiring 
pharmacological knowledge: mean values (95% CI), ranging from 1 (fully agree) to 5 (fully 
disagree) 
 I. Psychiatrists 
(n =81) 
II. Patients 
(n =83) 
III. Relatives 
(n =91) 
Statistical 
analysesa 
Advantages     
Depot antipsychotics have more 
advantages than disadvantages 
2.99 (2.73-3.25) 3.23 (2.96-3.49) 2.69 (2.46-2.91) F =4.9 
Depot antipsychotics have more 
advantages than oral formulations 
3.51 (3.28-3.73) 3.51 (3.23-3.79) 2.72 (2.49-2.95) F =13.8*  
I and II > III 
Depot antipsychotics provide more 
security to the patient than do oral 
antipsychotics 
2.89 (2.62-3.17) 3.51 (3.23-3.79) 2.47 (2.26-2.68) F =16.8*  
II > III 
With oral medication it is more likely to 
relapse 
2.86 (2.56-3.15) 3.58 (3.29-3.87) 2.68 (2.44-2.92) F =11.9*  
II > I and III 
With depot medication patients are not 
reminded of their disorder each day 
2.49 (2.20-2.77) 2.90 (2.60-3.20) 2.17 (1.95-2.40) F =7.5* 
II > III 
With oral medication it is more likely to 
forget the taking  
2.42 (2.18-2.66) 3.30 (2.98-3.62) 2.16 (1.93-2.40) F =20.2* 
II > I and III 
Disadvantages     
Depot antipsychotics are more 
stigmatising to the patient 
3.68 (3.39-3.96) 3.04 (2.72-3.36) 3.18 (2.95-3.42) F =5.4 
Depot antipsychotics constrict the 
patients’ freedom and autonomy  
3.43 (3.13-3.73) 2.48 (2.17-2.79) 3.00 (2.75-3.25) F =10.7*  
I > II 
Oral antipsychotics constrict the patients’ 
freedom and autonomy  
3.75 (3.50-4.01) 3.60 (3.26-3.94) 3.06 (2.81-3.31) F =6.8*  
I > III 
Depot antipsychotics induce more side 
effects than oral antipsychotics 
3.55 (3.30-3.79) 
 
2.82 (2.60-3.05) 
 
3.05 (2.88-3.21) 
 
F =11.5*  
I >II 
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The injections of depot antipsychotics are 
very painful 
3.83 (3.59-4.07) 2.51 (2.22-2.80) 3.18 (2.99-3.37) F =28.7* 
I > III > II 
The injections of depot antipsychotics are 
complex 
3.68 (3.40-3.95) 2.88 (2.60-3.17) 3.22 (2.99-3.45) F =8.6* 
I > II  
Knowledge     
With depot application a smaller amount 
of the acting agent is sufficient 
2.04 (1.79-2.29) 3.04 (2.80-3.28) 2.85 (2.70-3.00) F =23.3* 
I < II and III 
With depot application the blood 
concentration of the acting agent is more 
stable than with oral application  
1.87 (1.65-2.10) 2.80 (2.55-3.05) 2.89 (2.69-3.08) F =24.8* 
I < II and III 
The costs of depot antipsychotics are 
much higher than the costs of a 
comparable oral neuroleptic 
3.67 (3.42-3.91) 2.83 (2.62-3.04) 2.99 (2.88-3.09) F =20.6* 
I > II and III 
In the group of oral antipsychotics one 
can chose among much more 
preparations. 
1.27 (1.12-1.43) 2.16 (1.93-2.40) 1.98 (1.78-2.17) F =21.7* 
I < II and III 
aANOVA, multiple comparison with Tukey-HSD post-hoc test, *significant at P < 0.003 Bonferroni adjustment, df=2 
 
 
 
